Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 1:03 AM ET


Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1987

2,359 Employees





Key Executives for MedImmune, LLC

Vice President of Finance
Chief Operating Officer
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Age: 60
Executive Vice President
Compensation as of Fiscal Year 2015.

MedImmune, LLC Key Developments

Medimmune Appoints Christopher Rhodes as Head of Cardiovascular, Metabolic Disease Research

MedImmune announced that Christopher Rhodes, Ph.D., has joined the company as Vice President, Cardiovascular and Metabolic Disease (CVMD) Research. Dr. Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, and contributing to the product development goals and vision across the CVMD therapeutic area. Dr. Rhodes joins MedImmune from the University of Chicago, where he was Research Director at the Kovler Diabetes Center, the Kovler Family Professor of Endocrinology, and Chair of the Committee on Molecular Metabolism & Nutrition and Biomedical Sciences Cluster of the Biological Sciences Division.

MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM

MedImmune, LLC Presents at BIO International Convention 2015, Jun-16-2015 02:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM

MedImmune, LLC Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 08:40 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Reginald Seeto, Head of Partnering & Strategy and Vice President.

Similar Private Companies By Industry

Company Name Region
Mikart, Inc. United States
Pharmaceutical Holdings Corporation United States
Roche Pharma, Inc. United States
Anchen Incorporated United States
IDEKOS United States

Recent Private Companies Transactions

November 4, 2014
Definiens AG
August 20, 2014
MedImmune, LLC, Global Rights to Ethyol®

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at